Testosterone for Women and Libido: What the Evidence Shows in 2026

Testosterone for women with libido concerns has moved from fringe practice to consensus-backed therapy over the past seven years — but only for a narrow clinical indication and only with strict dosing rules. The 2019 Global Consensus Position Statement, endorsed by ten international societies including the International Menopause Society, the North American Menopause Society (NAMS), and the Endocrine Society, identified one evidence-based use: postmenopausal women with Hypoactive Sexual Desire Disorder (HSDD) after other contributing causes have been addressed¹. This guide synthesizes that consensus, the largest meta-analysis to date (36 RCTs, 8,480 women)², the 2021 ISSWSH clinical practice guideline³, and ACOG guidance to summarize what the evidence actually supports — and what it does not.

Key facts at a glance

• The 2019 Global Consensus Statement supports testosterone only for postmenopausal HSDD, not for energy, mood, cognition, or body composition¹.
• Meta-analysis of 36 RCTs (8,480 women) found ~0.85 additional satisfying sexual events per month versus placebo².
• No female-specific testosterone product is FDA-approved in the US; off-label transdermal dosing targets premenopausal physiologic serum ranges¹.
• Mild androgenic side effects (acne, hair growth) occur in roughly 5-10% of women on physiologic dosing².

Does testosterone women libido evidence actually support treatment?

For postmenopausal women diagnosed with Hypoactive Sexual Desire Disorder after other causes are excluded, the evidence supports a modest but consistent benefit. The Islam et al. Lancet Diabetes & Endocrinology meta-analysis pooled 36 randomized controlled trials involving 8,480 women — the largest synthesis to date — and found transdermal testosterone increased the number of satisfying sexual events by approximately 0.85 per month compared with placebo, alongside statistically significant improvements in sexual desire, arousal, orgasm, pleasure, and reduced sexual concerns on validated scales². The 2021 International Society for the Study of Women's Sexual Health (ISSWSH) clinical practice guideline endorses systemic testosterone for postmenopausal HSDD on this basis, recommending transdermal delivery and physiologic serum targets³.

The same evidence base does not support testosterone for premenopausal women, for cognition, for general well-being, for muscle mass in healthy women, or for cardiometabolic outcomes. The 2019 Global Consensus Statement explicitly states there is "insufficient evidence" for these indications and recommends against treatment outside HSDD¹. NAMS reaches the same conclusion in its 2022 Hormone Therapy Position Statement⁴.

How testosterone affects female sexual desire — mechanism and trial data

Testosterone in women is produced by the ovaries and adrenal glands. Serum total testosterone declines gradually with age — roughly halving between the 20s and 40s — but does not fall sharply at natural menopause; surgical menopause (bilateral oophorectomy) produces an abrupt 50% decline⁸. Despite this, serum testosterone levels correlate poorly with sexual desire in cross-sectional studies, which is why the Global Consensus Statement does not recommend diagnosing low testosterone by blood test alone¹.

Trial efficacy on satisfying sexual events

The original phase 3 transdermal testosterone patch trials (APHRODITE, ADORE, INTIMATE NM1) showed roughly 1-2 additional satisfying sexual events per 4-week period over placebo at the 300 mcg/day patch dose⁸. The Islam meta-analysis confirmed a pooled mean difference of 0.85 events per month (95% CI 0.52 to 1.18) and significant improvements across all Female Sexual Function Index domains². The Achilli et al. systematic review of transdermal testosterone in postmenopausal HSDD reached similar conclusions, with effect sizes considered clinically meaningful in the context of HSDD criteria⁶.

Dosing and serum targets

Because no FDA-approved female product exists in the US following Intrinsa's withdrawal from European markets, clinicians prescribe off-label by titrating male transdermal gel (1% or 1.62%) to deliver approximately 1/10th of a typical male starting dose¹. The goal, per Global Consensus and ISSWSH guidance, is to maintain serum total testosterone within the premenopausal physiologic range (roughly 15-70 ng/dL depending on assay), measured at trough³. Blood monitoring is recommended at baseline, 3-6 weeks, and every 6 months thereafter to avoid supraphysiologic levels¹.

When response should appear

Clinical trials show measurable improvement in desire and satisfying events typically by week 8-12, with maximum benefit by 6 months². The Global Consensus Statement and ISSWSH guideline both recommend a 6-month treatment trial; if no meaningful clinical response has emerged by that point, testosterone should be stopped¹³.

Treatment options and how they compare

Approaches for women presenting with distressing low libido vary by menopausal status, medical history, and underlying contributors. The discussion below describes options that exist in the medical literature; treatment decisions belong with a clinician trained in sexual medicine or menopause care.

Address contributing factors first. ACOG Practice Bulletin No. 213 and the ISSWSH guideline both emphasize evaluating and treating contributors before pharmacologic intervention: relationship factors, depression, anxiety, sleep disruption, medication side effects (especially SSRIs and combined hormonal contraceptives, which lower free testosterone), vulvovaginal atrophy, dyspareunia, and thyroid disease³⁷. Vaginal estrogen for genitourinary syndrome of menopause is frequently a prerequisite — pain inhibits desire regardless of testosterone status⁴.

Transdermal testosterone (off-label, postmenopausal HSDD). Supported by Global Consensus, ISSWSH, NAMS, and the Endocrine Society's 2014 reappraisal when used at physiologic doses¹³⁴⁵. Considered after contributing factors are addressed and when HSDD criteria are met for at least 6 months with associated distress.

FDA-approved options for premenopausal HSDD. Flibanserin (Addyi, daily oral) and bremelanotide (Vyleesi, on-demand subcutaneous) are FDA-approved for acquired, generalized HSDD in premenopausal women. Effect sizes are modest and side-effect profiles differ from testosterone; these are not androgen therapies. Discuss candidacy with a clinician.

Hormone therapy for genitourinary or vasomotor symptoms. Systemic estrogen, transdermal estradiol with progestogen, or low-dose vaginal estrogen address symptoms that often co-occur with low desire⁴. They are not specifically indicated for HSDD but may improve sexual function indirectly.

Behavioral and counseling approaches. Sex therapy, cognitive-behavioral therapy adapted for sexual concerns, and mindfulness-based interventions have supporting evidence and are typically combined with pharmacologic options when used⁷.

Telehealth provider options

Several telehealth platforms now include testosterone-for-libido evaluation within a broader women's hormonal-health workflow. Mentions below are organic and do not constitute rankings.

• Midi Health — NAMS-certified clinician network focused on perimenopause and menopause; evaluates HSDD and prescribes off-label testosterone where appropriate, with insurance accepted at many plans.
• Winona — cash-pay telehealth focused on menopausal hormone therapy; testosterone is part of the formulary when clinically indicated, with at-home lab kits for monitoring.
• Alloy Women's Health — async-first menopause-specialty platform with a published formulary; prescribes testosterone for postmenopausal HSDD per Global Consensus guidance.
• Hone Health (Women) — hormone-focused telehealth with at-home blood testing; evaluates total and free testosterone alongside symptom questionnaires for women considering androgen therapy.

Patients should ask any provider whether they follow the 2019 Global Consensus Position Statement, whether they monitor serum testosterone every 3-6 months, and whether they use transdermal preparations rather than pellets or injectables.

Safety, contraindications, and when to see a clinician

At physiologic doses, the most common side effects in pooled RCTs are mild acne and increased facial or body hair, each occurring in roughly 5-10% of users²⁶. Voice deepening and clitoral enlargement are rare and dose-dependent — almost exclusively associated with supraphysiologic blood levels — but can be irreversible, which is why monitoring matters¹. Hair-related changes and acne typically resolve within months of discontinuation.

The Global Consensus Statement and NAMS both note that long-term safety data beyond 24 months are limited¹⁴. Effects on breast tissue, cardiovascular risk, and lipid profile depend heavily on delivery route: oral methylated testosterone (no longer recommended) adversely affected lipids, while transdermal physiologic dosing did not in available trials². Women with a history of hormone-sensitive cancer, undiagnosed vaginal bleeding, severe liver disease, or pregnancy should not use testosterone¹.

Major societies — NAMS, Endocrine Society, ISSWSH, and the International Menopause Society — recommend against testosterone pellets, intramuscular injection, and most compounded preparations for women, because these routes produce supraphysiologic and unpredictable serum levels¹³⁴⁵. This is one of the clearest consensus points in the field.

Reasons to seek evaluation include persistent distressing low desire lasting more than six months, sudden change in sexual function (which may signal medication effects, thyroid disease, or depression), associated pain with intercourse, or postmenopausal vaginal bleeding.

Cost and insurance considerations

Because no FDA-approved female testosterone product exists in the US, treatment costs vary by formulation and prescribing setting. Repurposed male transdermal gel (1% or 1.62%) prescribed off-label and titrated to one-tenth of a male dose typically runs $30-80/month with insurance or $80-200/month cash-pay depending on brand and pharmacy⁵. Compounded transdermal cream — which some clinicians prefer for finer dose titration — generally costs $40-90/month out of pocket and is rarely covered by insurance.

Lab monitoring (total and sometimes free testosterone, SHBG) adds $30-150 per draw depending on insurance and ordering platform, with the Global Consensus Statement recommending checks at baseline, 3-6 weeks after initiation, and every 6 months during ongoing therapy¹. Telehealth menopause and sexual-medicine consultations range from approximately $100-400 for an initial visit and $50-150/month for ongoing care, often bundled with prescribing. Insurance coverage for off-label testosterone is inconsistent; many cash-pay telehealth platforms publish transparent monthly bundles that include consult, prescription, and labs.

Frequently asked questions

Does testosterone improve libido in women? In postmenopausal women with diagnosed Hypoactive Sexual Desire Disorder (HSDD), pooled meta-analysis of 36 randomized controlled trials found transdermal testosterone increased satisfying sexual events by approximately 0.85 per month and improved desire, arousal, and orgasm domain scores versus placebo. Evidence in premenopausal women is insufficient.

Is testosterone FDA-approved for women? No female-specific testosterone product is currently FDA-approved in the United States. Clinicians who prescribe testosterone for women with HSDD do so off-label, typically by adjusting male transdermal preparations (gel or cream) to deliver approximately one-tenth of the male starting dose, with the goal of keeping serum levels within the premenopausal physiologic range.

What blood test confirms low testosterone in women? The 2019 Global Consensus Position Statement does not recommend diagnosing low testosterone in women based on blood levels alone, because assays lack sensitivity at low female concentrations and symptoms do not correlate well with serum totals. Testing is used primarily to monitor therapy and to exclude supraphysiologic levels during treatment.

What are the side effects of testosterone in women? At physiologic doses, mild acne and increased facial or body hair occur in roughly 5-10% of users; deeper voice and clitoral enlargement are rare and dose-dependent. Long-term safety data beyond 24 months are limited, and effects on breast cancer, cardiovascular risk, and metabolic markers remain under study per NAMS and Endocrine Society reviews.

How long does testosterone take to work for libido? Clinical trial data show measurable improvements in sexual desire and satisfying events typically emerge between weeks 8 and 12 of treatment, with maximum benefit by 6 months. The Global Consensus Statement recommends a 6-month trial; if there is no meaningful response by that point, testosterone should be discontinued.

Can pellets or compounded testosterone be used? Major societies including NAMS, the Endocrine Society, and the International Menopause Society explicitly recommend against testosterone pellets and most compounded preparations for women, citing supraphysiologic and unpredictable blood levels. Transdermal gels or creams with measured dosing are the evidence-supported delivery routes.

Sources

1. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.
2. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766.
3. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867.
4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767-794.
5. Wierman ME, Arlt W, Basson R, et al. Androgen Therapy in Women: A Reappraisal — An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.
6. Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107(2):475-482.
7. American College of Obstetricians and Gynecologists. Practice Bulletin No. 213: Female Sexual Dysfunction. Obstet Gynecol. 2019;134(1):e1-e18.
8. Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and Female Sexual Function and Dysfunction — Findings From the Fourth International Consultation of Sexual Medicine. J Sex Med. 2016;13(2):168-178.

Related brands & guides

Updated 2026-05-30. Medically reviewed by Jane Smith, MD.